Anal Fistula- Pipeline Insight, 2024

Anal Fistula- Pipeline Insight, 2024

DelveInsight’s, “Anal Fistula- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Anal Fistula pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Anal Fistula: Understanding

Anal Fistula: Overview

An anal fistula is a small tunnel that develops between the end of the bowel and the skin near the anus (where poo leaves the body).They're usually the result of an infection near the anus causing a collection of pus (abscess) in the nearby tissue. When the pus drains away, it can leave a small channel behind. Anal fistulas can cause unpleasant symptoms, such as discomfort and skin irritation, and will not usually get better on their own. Surgery is recommended in most cases. Symptoms of an anal fistula can include: skin irritation around the anus, a constant, throbbing pain that may be worse when person sits down, move around, poo or cough, smelly discharge from near the anus, passing pus or blood when person has to poo, swelling and redness around the anus and a high temperature (fever) if the person also have an abscess. Most anal fistulas develop after an anal abscess. One can get one if the abscess does not heal properly after the pus has drained away. Less common causes of anal fistulas include: Crohn's disease, diverticulitis, hidradenitis suppurativa, infection with tuberculosis (TB) or HIV or a complication of surgery near the anus. Anal fistulas usually require surgery as they rarely heal if left untreated. There are several different procedures. The best option will depend on the position of fistula and whether it's a single channel or branches off in different directions. The most common type of surgery for anal fistulas is a fistulotomy. This involves cutting along the whole length of the fistula to open it up so it heals as a flat scar. A fistulotomy is the most effective treatment for many anal fistulas, although it's usually only suitable for fistulas that do not pass through much of the sphincter muscles, as the risk of incontinence is lowest in these cases. Like any type of treatment, treatment for anal fistulas carries a number of risks. The main risks are: infection – this may require a course of antibiotics; severe cases may need to be treated in hospital, recurrence of the fistula – the fistula can sometimes recur despite surgery and bowel incontinence – this is a potential risk with most types of anal fistula treatment, although severe incontinence is rare and every effort is made to prevent it.

“Anal Fistula- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anal Fistula pipeline landscape is provided which includes the disease overview and Anal Fistula treatment guidelines. The assessment part of the report embraces, in depth Anal Fistula commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anal Fistula collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Anal Fistula R&D. The therapies under development are focused on novel approaches to treat/improve Anal Fistula.

Anal Fistula Emerging Drugs Chapters

This segment of the Anal Fistula report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anal Fistula Emerging Drugs

• Stempeucel: Stempeutics

Stempeucel® is a flagship product. It is an on-demand, off-the-shelf product based on pooled, allogeneic Mesenchymal Stromal Cells (MSC) derived from bone marrow of healthy, adult volunteers. In August 2020, Drug Controller General of India (DCGI) has granted manufacturing and marketing approval of Stempeucel® product for the treatment of CLI due to Buerger’s Disease and CLI due to Atherosclerotic Peripheral Arterial Disease. Stempeucel® becomes the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved Globally for CLI indication. Stempeucel® is being developed for the treatment of Knee Osteoarthritis (OA), Diabetic Foot Ulcer (DFU), Perianal Fistula (PAF) and Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 pneumonia. An open label, single arm, investigator initiated Phase I/II study to assess the safety and efficacy of local administration of Stempeucel® in Patients with perianal fistulizing Crohn's disease.

Further product details are provided in the report……..

Anal Fistula: Therapeutic Assessment

This segment of the report provides insights about the different Anal Fistula drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Anal Fistula

There are approx. 5+ key companies which are developing the therapies for Anal Fistula. The companies which have their Anal Fistula drug candidates in the most advanced stage, i.e. phase I/II include, Stempeutics.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Anal Fistula pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anal Fistula: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anal Fistula therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anal Fistula drugs.

Anal Fistula Report Insights

• Anal Fistula Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Anal Fistula Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Anal Fistula drugs?
• How many Anal Fistula drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anal Fistula?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anal Fistula therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anal Fistula and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Stempeutics
• Angiocrine Bioscience
• Carephar
• Ossium Health

Key Products

• Stempeucel
• AB-207
• Ossium vBM-MSC